Reviewer's report

Title: KRAS, BRAF Genotyping Reveals Genetic Heterogeneity of Ovarian Borderline Tumours and Associated Implants

Version: 3 Date: 6 August 2013

Reviewer: Rachel Grisham

Reviewer's report:

This is an interesting article describing mutation profiling of primary serous borderline ovarian tumors and their associated noninvasive implants.

Minor Essential Revisions

1. The authors report here an unusually high number of concurrent KRAS and BRAF mutations identified within a single tumor tissue or implant (up to 26.7% of patients). As the authors acknowledge, these mutations are generally found to be mutually exclusive, and multiple prior publications examining serous borderline disease have confirmed these mutations to be mutually exclusive. I recommend that the authors confirm their results using Sanger sequencing.

2. The same sentence is repeated in lines 82 and 84 of the manuscript.

3. Table 1, it should be made clear how many of the implants displayed each mutation profile (i.e. in patient 16 there were 19 implants examined and 3 mutation profiles reported, how many implants displayed each profile?)

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests